close
close

Eli Lilly is investing $4.5 billion in drug manufacturing and study drug production

The new facility will support the manufacturing of various molecular therapies. Photo credit: Eli Lilly and Company/PR Newswire.

Eli Lilly has announced a $4.5 billion investment to create the Lilly Medicine Foundry for drug production and clinical trial drug manufacturing.

The facility will be located in Indiana's LEAP Research and Innovation District in Lebanon and will combine advanced manufacturing with drug development.

It is intended to enhance Lilly's capabilities in producing drugs for clinical trials while exploring manufacturing solutions.

This initiative is expected to optimize processes, increase trial drug capacity, and reduce both costs and environmental impact. The facility will enable the production of various molecular therapies, including small molecules, biologics and nucleic acid therapies.

Medicine Foundry's technological advances will be implemented across Lilly's manufacturing network for broader application.

Its strategic location within the LEAP District promotes synergies with Lilly Research Laboratories in Indianapolis and the company's existing manufacturing sites in Lebanon.

Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain a competitive advantage.

Company profile – free sample

Your download email will arrive shortly

We are convinced of the unique quality of our company profiles. However, because we want you to make the most beneficial decision for your business, we offer you a free sample that you can download by filling out the form below

By GlobalData







Visit our Privacy Policy for more information about our Services, how we may use, process and share your personal data, including information about your rights in relation to your personal data and how you can opt-out of future marketing communications. Our Services are intended for corporate subscribers and you warrant that the email address provided is your corporate email address.

David Ricks, chairman and CEO of Eli Lilly, said: “As we accelerate our work to discover new medicines for the most challenging diseases, we continue to invest in cutting-edge infrastructure to support our growing pipeline.”

“This new complex will not only deliver high-quality medicines for our clinical trials, but will also further strengthen our process development and expand our manufacturing capabilities to accelerate the delivery of next-generation medicines to patients around the world.”

The new facility builds on Lilly's ongoing expansion in Lebanon. In May 2022, Lilly announced a $2.1 billion investment in two new active ingredients and modalities sites.

These locations broke ground in April 2023 with an additional investment of $1.6 billion.

In May 2024, Lilly committed an additional $5.3 billion to increase active pharmaceutical ingredient manufacturing capacity, focusing on treating diabetes and obesity.

In August 2024, Eli Lilly increased its 2024 sales forecast following second-quarter financial results due to the success of weight-loss drug Zepbound.


You may also like...